Literature DB >> 21537452

Evaluation of neprilysin sequence variation in relation to CSF β-Amyloid levels and Alzheimer disease risk.

Mia E Blomqvist, Shane McCarthy, Kaj Blennow, Björn Andersson, Jonathan A Prince.   

Abstract

Neprilysin (NEP) is a principal peptidase involved in the degradation of β-amyloid (Aβ), and as such its encoding gene (MME) has been the target of numerous genetic association studies on Alzheimer disease. Here, in order to attempt replication of previous findings we have investigated several single nucleotide polymorphisms (SNPs) that have been claimed to be associated with AD. A key feature of the present study is the complementary investigation of both AD risk and quantitative measures of AD severity, including cerebrospinal (CSF) fluid levels of AP1-42. In contrast to the effects of APOE, none of these measures are detectably influenced by genetic polymorphism in the MME region. We thus, fail to find support for previous results suggesting that MME impacts AD.

Entities:  

Keywords:  Alzheimer disease; MME; Metalloendopeptidase; Neprilysin; Polymorphism; β-Amyloid

Year:  2010        PMID： 21537452      PMCID： PMC3076750     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN： 1948-1756


  29 in total

1.  A new statistical method for haplotype reconstruction from population data.

Authors:  M Stephens; N J Smith; P Donnelly
Journal:  Am J Hum Genet       Date:  2001-03-09       Impact factor: 11.025

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

3.  Metabolic regulation of brain Abeta by neprilysin.

Authors:  N Iwata; S Tsubuki; Y Takaki; K Shirotani; B Lu; N P Gerard; C Gerard; E Hama; H J Lee; T C Saido
Journal:  Science       Date:  2001-05-25       Impact factor: 47.728

4.  Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition.

Authors:  N Iwata; S Tsubuki; Y Takaki; K Watanabe; M Sekiguchi; E Hosoki; M Kawashima-Morishima; H J Lee; E Hama; Y Sekine-Aizawa; T C Saido
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease.

Authors:  Masaya Oda; Hiroyuki Morino; Hirofumi Maruyama; Hideo Terasawa; Yuishin Izumi; Tsuyoshi Torii; Ken Sasaki; Shigenobu Nakamura; Hideshi Kawakami
Journal:  Neurosci Lett       Date:  2002-03-01       Impact factor: 3.046

6.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

Authors:  M Sumitomo; R Shen; M Walburg; J Dai; Y Geng; D Navarro; G Boileau; C N Papandreou; F G Giancotti; B Knudsen; D M Nanus
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

7.  Neutrophil neutral endopeptidase variation and its regulation by opioid peptides.

Authors:  T Balog; T Marotti; M Abramić; I Beusan-Svoboda; S Sobocanec; I Hrsak
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

8.  Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.

Authors:  K Yasojima; H Akiyama; E G McGeer; P L McGeer
Journal:  Neurosci Lett       Date:  2001-01-12       Impact factor: 3.046

9.  Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes.

Authors:  N Sodeyama; H Mizusawa; M Yamada; Y Itoh; E Otomo; M Matsushita
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 10.  Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

Authors:  Julie A Carson; Anthony J Turner
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372
View more
  5 in total

Review 1.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

2.  Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.

Authors:  Scott Miners; Zoë van Helmond; Rachel Barker; Peter A Passmore; Janet A Johnston; Stephen Todd; Bernadette M McGuinness; Francesco Panza; Davide Seripa; Vincenzo Solfrizzi; Seth Love; Jonathan A Prince; Patrick G Kehoe
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

3.  Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.

Authors:  Hui-Zhen Wang; Rui Bi; Deng-Feng Zhang; Guo-Dong Li; Xiao-Hong Ma; Yiru Fang; Tao Li; Chen Zhang; Yong-Gang Yao
Journal:  Mol Neurobiol       Date:  2015-09-11       Impact factor: 5.590

Review 4.  Gene therapy in Alzheimer's disease - potential for disease modification.

Authors:  Per Nilsson; Nobuhisa Iwata; Shin-ichi Muramatsu; Lars O Tjernberg; Bengt Winblad; Takaomi C Saido
Journal:  J Cell Mol Med       Date:  2010-02-16       Impact factor: 5.310

5.  Association of Genes Involved in the Metabolic Pathways of Amyloid-β and Tau Proteins With Sporadic Late-Onset Alzheimer's Disease in the Southern Han Chinese Population.

Authors:  Xuewen Xiao; Bin Jiao; Xinxin Liao; Weiwei Zhang; Zhenhua Yuan; Lina Guo; Xin Wang; Lu Zhou; Xixi Liu; Xinxiang Yan; Beisha Tang; Lu Shen
Journal:  Front Aging Neurosci       Date:  2020-11-06       Impact factor: 5.750
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.